



*Solagran Limited*

Solagran Limited  
ACN 002 592 396  
Level 1  
480 St Kilda Road  
Melbourne 3004  
Victoria, Australia  
Tel 61 3 9820 2699  
Fax 61 3 9820 3155

20 July 2010

## **Company Announcement**

### **Market Update**

#### **Ropren Sales in Russia**

Solagran is pleased to confirm the following progress in relation to Ropren sales in Russia.

Negotiations with Imperia Pharma in St Petersburg have been finalised with the company placing an initial order for 70 courses of Ropren. Imperia Pharma are the leading distributor of pharmaceutical products to hospitals and pharmacies in St Petersburg and the St Petersburg region. They will start by allocating the product to 20 hospitals in the region and seek to expand their coverage of hospitals over the next 2-3 months.

Solagran has completed contractual arrangements with Vitamax for distribution of Ropren in Russia. Their initial order of 50 courses will be delivered shortly. Vitamax distribute pharmaceutical products to more than 150 hospitals and specialised pharmacies across Russia.

Solagran is finalising negotiations with Kuzbass Pharma for distribution of Ropren in the Kemerovo region. Their initial order of 40 courses will be allocated to 8 hospitals. Solagran expects arrangements to be finalised by the beginning of September.

Solagran has engaged Stolichnye Apteki to distribute Ropren to selected hospitals and pharmacies in the Moscow region in addition to the hospitals which are already using the product in Moscow.

Solagran is continuing work on a number of other distribution relationships within the country either via direct negotiation with hospitals or via pharmaceutical distribution groups within particular regions.

To conclude, Ropren will be available in at least 75 hospitals in Russia by the end of September this year and will continue to be available in selected pharmacy networks across the country. Given the initial orders placed by the distributors noted above are anticipated to increase materially over the next few months, Solagran will update the market in relation to its sales forecast around the end of September 2010.

## **SibEX Acquisition of Minority Interest**

Solagran is pleased to advise that the acquisition of the remaining 15% of SibEX LLC has now been completed. Consideration for the acquisition will be a combination of cash and shares over the next 12 months.

## **Solagran Son Pharmaceutical Distribution Licence**

Further to our announcement of 5 February 2010, Solagran is pleased to advise that all formalities have now been completed for the issue of a Pharmaceutical Distribution Licence to its wholly owned subsidiary in Russia, Solagran Son LLC. Solagran has been advised by the Commission that the licence will be issued by the second week of August. Upon receipt of the licence Solagran Son LLC will be able to control the distribution of all of its registered pharmaceutical products both domestically and overseas.

## **Bioeffective A – BANA Approval Russia**

As mentioned in our announcement earlier this month, Solagran confirms that Bioeffective A is now registered in Russia as a BANA (Biologically Active Nutritional Additive). This registration allows Solagran to conduct multi-centre international trials of the product and, if considered viable, to pursue commercial distribution in its country of origin.

Yours faithfully



Justyn Stedwell  
**Company Secretary**  
**On behalf of the Board of Directors**  
**Solagran Limited**